• The primary outcome will be mean differences in adherence over 365 days after randomization by comparing the two intervention groups with the control group. [ Time Frame: one year ]
  

• Mean differences in adherence over 180 days after randomization by comparing the two intervention groups with the control group. [ Time Frame: 180 days ]
  
• Mean differences in adherence over 270 days after randomization by comparing the two intervention groups with the control group. [ Time Frame: 270 days ]
  
• If the pre-specified effect on mean adherence is measured, change in LDL-C will also be assessed. [ Time Frame: 365 days ]
  
• Complete discontinuation defined as more than 182 consecutive days of the one year observation period uncovered (<50%). [ Time Frame: one year ]
  

Medication non-adherence represents an important threat to the health of the Western people. A large number of pharmacy records based studies demonstrated that adherence to lipid lowering treatment in daily practice is substantially worse compared to adherence observed in the controlled setting of randomized controlled trials. In addition, the relationship between non-adherence with statin-treatment assessed with pharmacy records and cardiovascular outcomes has been convincingly demonstrated. This implies that pharmacy records can and should be used to identify non-adherent patients and thus patients at risk for major cardiovascular events. Using this data, community pharmacists can play a more substantive role in developing the concept of pharmaceutical care. The objective of the study is to test the effectiveness of a community pharmacist-led intervention to increase adherence to lipid lowering treatment.